AstraZeneca to put CVRM and R&I diseases in the spotlight at Nursing Live
Nursing Live’s top-tier sponsor to host special promotional sessions only for healthcare professionals focused on insights into cardiovascular, renal, and metabolism conditions and respiratory and immunology diseases.
London, UK, Thursday 09 November 2023: Nursing Live’s top tier sponsor AstraZeneca, a global leader in the discovery, development, and commercialisation of prescription medicines and biopharmaceuticals, has announced details of its symposia and workshops at Nursing Live, focusing on addressing cardiovascular, renal, and metabolism (CVRM) conditions, as well as respiratory and immunology diseases (R&I).
During the event, AstraZeneca will host four symposia to shed light on chronic health conditions. These sessions aim to drive knowledge exchange and empower nursing professionals with evolving science and compelling real-world evidence to advance collaborative care to improve patient outcomes.
The symposia will cover the following essential topics within CVRM and R&I, which have been organised and fully funded by AstraZeneca:
Collaborative care for patients with cardiorenal risk: This session will emphasise the importance of adopting a multidisciplinary approach when managing patients with type 2 diabetes (T2D) who are at a high risk of developing cardiorenal complications.
Transforming COPD care - Managing COPD patients: the prevalence & burden of comorbidities in COPD: This session will explore the health burden and associated risks for patients with COPD and CVD, emphasising the exacerbating impact of uncontrolled COPD.
Reduce over-reliance on SABAs in asthma: time to take action: Highlighting unmet needs in asthma management, this session will discuss the current NICE guidelines and recommended treatment options for effectively managing asthma. Nursing staff attending this session will gain insight into the latest evidence-based approaches for optimising care for their asthma patients.
Unravelling complex cases of Hyperkalaemia in the multi-morbid population: This session will examine the management of cardiovascular and renal patients with acute and chronic hyperkalaemia, exploring management approaches beyond traditional methods.
Commenting on AstraZeneca’s sponsorship of Nursing Live and their backing of the CRVM and R&I symposiums, Fiona Morgan, the Head of External Engagement at AstraZeneca UK, said: "We take immense pride in our support towards the nursing profession. The complexities and interconnections of cardiovascular, renal, and metabolism diseases highlight the urgency for a collaborative and integrated care approach. This approach is crucial to aid patients in managing their diseases and achieving positive outcomes.
Nurses play a pivotal role on the front lines, supporting patients with cardiorenal risk throughout their treatment journey. By providing education around the latest clinical developments, we are continuing to help upskill them as they deliver crucial care for patients.”
Rachel Armitage, Managing Director of RCNi, said: “We warmly welcome AstraZeneca’s support for Nursing Live, specifically for sponsored sessions dedicated to vital aspects of cardiovascular, renal & metabolism therapies, and respiratory and immunology care. It’s encouraging to see a global biopharmaceutical business like AstraZeneca recognising the key role that nursing staff play in the shaping and delivery of improved patient outcomes.
“AstraZeneca’s commitment to innovation, collaboration, and knowledge exchange are principles that have informed our approach to the Nursing Live event, and it’s great to be working with a major healthcare partner who shares similar values.”
During the event, healthcare professional attendees can learn more about AstraZeneca UK's active support for nursing staff by visiting Stand L28 in the Nursing Live Lifestyle Zone, where AstraZeneca medicines will be mentioned in this promotional stand.